Prelude Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 128

Market Cap: $299.3M

Website

Clinical Trials

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 2

Not yet recruiting

Conditions: Advanced Solid Tumor
Esophageal Cancer
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation

Interventions: Drug: PRT3789
Drug: pembrolizumab

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 60

Registration Number: NCT06682806

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
Advanced Solid Tumor
Non-small Cell Lung Carcinoma
SMARCA4 Mutation

Interventions: Drug: PRT7732

First Posted Date: 2024-08-19

Last Posted Date: 2024-12-19

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 104

Registration Number: NCT06560645

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 6 locations

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Mantle Cell Lymphoma (MCL)
Diffuse Large B-cell Lymphoma (DLBCL)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Richter's Syndrome
T-cell Lymphoma
Chronic Myelomonocytic Leukemia (CMML)

Interventions: Drug: PRT2527
Drug: Zanubrutinib
Drug: Venetoclax

First Posted Date: 2022-12-27

Last Posted Date: 2024-08-22

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 274

Registration Number: NCT05665530

Locations: 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 21 locations

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation

Interventions: Drug: PRT3789
Drug: Docetaxel

First Posted Date: 2022-12-06

Last Posted Date: 2024-10-23

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 186

Registration Number: NCT05639751

Locations: 🇫🇷
lnstitut Paoli Calmettes, Marseille, France
🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States

and more 24 locations

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Glioblastoma
Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancers
Malignant Mesothelioma
Sarcoma
Endometrial Cancer

Interventions: Drug: PRT3645

First Posted Date: 2022-09-14

Last Posted Date: 2024-07-01

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 22

Registration Number: NCT05538572

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 10 locations

A Study of PRT2527 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Sarcoma
Hormone Receptor Positive HER2 Negative Breast Cancer
Castrate Resistant Prostate Cancer
Non-small Cell Lung Cancer
Solid Tumors With Known MYC Amplification

Interventions: Drug: PRT2527

First Posted Date: 2021-12-16

Last Posted Date: 2023-12-11

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 30

Registration Number: NCT05159518

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

and more 5 locations

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Phase 1

Terminated

Conditions: Follicular Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia
Small Lymphocytic Lymphoma
B-cell Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndromes

Interventions: Drug: PRT1419
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2021-11-04

Last Posted Date: 2024-01-31

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 21

Registration Number: NCT05107856

Locations: 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States

and more 6 locations

A Study of PRT1419 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Sarcoma
Cervical Cancer
Head and Neck Cancer
Lung Cancer
Melanoma
Esophageal Cancer
Breast Cancer

Interventions: Drug: PRT1419

First Posted Date: 2021-04-08

Last Posted Date: 2023-03-15

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 26

Registration Number: NCT04837677

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 3 locations

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Multiple Myeloma
Acute Myeloid Leukemia
Non Hodgkin Lymphoma
Myelodysplastic Syndromes

Interventions: Drug: PRT1419

First Posted Date: 2020-09-10

Last Posted Date: 2022-11-15

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 16

Registration Number: NCT04543305

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 1 locations

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Phase 1

Completed

Conditions: Advanced Solid Tumor
Recurrent Glioma

Interventions: Drug: PRT811

First Posted Date: 2019-09-13

Last Posted Date: 2023-04-05

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 86

Registration Number: NCT04089449

Locations: 🇺🇸
The Ohio State University and Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy